Soligenix (SNGX) News Today → 41 banks launch ‘crypto dollar’ (From Stansberry Research) (Ad) Free SNGX Stock Alerts $0.33 -0.02 (-6.37%) (As of 11:21 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 7:30 AM | prnewswire.comSoligenix Announces Reverse Stock SplitMay 30 at 6:40 AM | americanbankingnews.comSoligenix, Inc. (NASDAQ:SNGX) Sees Significant Decrease in Short InterestMay 29 at 7:30 AM | prnewswire.comSoligenix Encourages Stockholders to Vote their Shares at the Annual MeetingMay 24, 2024 | prnewswire.comSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingMay 23, 2024 | prnewswire.comSoligenix Encourages Stockholders to Vote "FOR" Reverse Stock SplitMay 22, 2024 | finance.yahoo.comSoligenix, Inc. (SNGX)May 21, 2024 | finance.yahoo.comPRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the HorizonMay 21, 2024 | prnewswire.comSuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX ConferenceMay 20, 2024 | prnewswire.comSoligenix Encourages Stockholders to Vote Prior to Annual MeetingMay 16, 2024 | prnewswire.comPositive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical PracticeMay 14, 2024 | finance.yahoo.comSNGX: Second Confirmatory Phase 3 Trial of HyBryte™ in CTCL to Initiate Before End of 2024…May 13, 2024 | msn.comSNGX Stock Earnings: Soligenix Beats EPS, Misses Revenue for Q1 2024May 13, 2024 | finance.yahoo.comSoligenix First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2024 | prnewswire.comSoligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsMay 6, 2024 | prnewswire.comSoligenix to Present at Upcoming ConferencesApril 25, 2024 | prnewswire.comSoligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaApril 18, 2024 | prnewswire.comSoligenix Announces Pricing of $4.75 Million Public OfferingApril 17, 2024 | investing.comSoligenix gains orphan drug status for MarVax vaccineApril 17, 2024 | finance.yahoo.comSage Therapeutics' Parkinson's drug fails in mid-stage studyApril 17, 2024 | finance.yahoo.comNanoscope Therapeutics to Present at the World Orphan Drug Congress 2024April 16, 2024 | benzinga.comSNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™April 16, 2024 | finanznachrichten.deSOLIGENIX, INC.: FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionApril 15, 2024 | finance.yahoo.comWhy Is Penny Stock Soligenix Trading Higher On Monday?April 15, 2024 | proactiveinvestors.comSoligenix surges as MarVax vaccine secures Orphan Drug Designation from FDAApril 15, 2024 | marketwatch.comSoligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDAApril 15, 2024 | markets.businessinsider.comSoligenix's MarVax Gets Orphan Drug DesignationApril 15, 2024 | msn.comSoligenix stock soars 106% on FDA orphan drug statusApril 15, 2024 | investorplace.comWhy Are Stocks Up Today?April 15, 2024 | investorplace.comWhy Is Soligenix (SNGX) Stock Up 58% Today?April 15, 2024 | marketbeat.comTrading was temporarily halted for "SNGX" at 09:04 AM with a stated reason of "LULD pause."April 15, 2024 | finance.yahoo.comFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionApril 11, 2024 | msn.comSolinex Down On Orphan Drug DesignationApril 11, 2024 | finance.yahoo.comSNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™…April 11, 2024 | markets.businessinsider.comSoligenix's SuVax Granted FDA Orphan Drug Designation For Prevention Of Sudan Ebolavirus InfectionApril 11, 2024 | prnewswire.comFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus InfectionApril 3, 2024 | prnewswire.comSoligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines AgencyMarch 20, 2024 | finance.yahoo.comSNGX: Discussions Continue with FDA Regarding Second Phase 3 Study for HyBryte™ in CTCL…March 15, 2024 | investorplace.comSNGX Stock Earnings: Soligenix Beats EPS, Beats Revenue for Q4 2023March 15, 2024 | benzinga.comRecap: Soligenix Q4 EarningsMarch 15, 2024 | prnewswire.comSoligenix Announces Recent Accomplishments and Year End 2023 Financial ResultsFebruary 8, 2024 | finance.yahoo.comSoligenix Announces Formation of Behçet's Disease Medical Advisory BoardFebruary 1, 2024 | thestreet.comSoligenix Inc.January 26, 2024 | finanznachrichten.deSoligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVJanuary 26, 2024 | finance.yahoo.comSoligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJanuary 25, 2024 | finance.yahoo.comSoligenix to Present at The Microcap ConferenceJanuary 10, 2024 | finance.yahoo.comSNGX: Phase 2a Psoriasis Trial Achieves Clinical Success…January 8, 2024 | marketwatch.comSoligenix Shares Rise 8% After SGX945 Gets FDA Fast Track DesignationJanuary 8, 2024 | finance.yahoo.comFDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseJanuary 4, 2024 | markets.businessinsider.comSoligenix Reports Positive Preliminary Results From Phase 2a Study Of SGX302 In PsoriasisJanuary 4, 2024 | finance.yahoo.comSoligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this small stock before coming AI Tidal Wave (Ad)The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture. Get the name and ticker symbol for free - just click here. SNGX Media Mentions By Week SNGX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNGX News Sentiment▼0.660.82▲Average Medical News Sentiment SNGX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNGX Articles This Week▼61▲SNGX Articles Average Week Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CytoMed Therapeutics News Today Bullfrog AI News Today Sol-Gel Technologies News Today BriaCell Therapeutics News Today Iterum Therapeutics News Today Biora Therapeutics News Today Cumberland Pharmaceuticals News Today Sensei Biotherapeutics News Today MEI Pharma News Today NeuroBo Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNGX) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBill Clinton Backing Biden Replacement???The Freeport SocietyBUY ALERT: Billionaires piling into this asset classReagan Gold GroupThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBuy this small stock before coming AI Tidal WaveChaikin Analytics41 banks launch ‘crypto dollar’Stansberry ResearchDems have chosen Biden replacement?Paradigm PressGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
